Incorporation of two doctors to the R&D&i within the "Torres Quevedo" program 2020 call


No votes yet
 
Related
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024